Notice: This company has been marked as potentially delisted and may not be actively trading. TenX Keane Acquisition (TENK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesOwnershipShort InterestTrends TENK vs. COCP, PULM, BLRX, PIRS, MIRA, BTAI, CYTH, GLYC, SPRB, and ENLVShould you be buying TenX Keane Acquisition stock or one of its competitors? The main competitors of TenX Keane Acquisition include Cocrystal Pharma (COCP), Pulmatrix (PULM), BioLineRx (BLRX), Pieris Pharmaceuticals (PIRS), MIRA Pharmaceuticals (MIRA), BioXcel Therapeutics (BTAI), Cyclo Therapeutics (CYTH), GlycoMimetics (GLYC), Spruce Biosciences (SPRB), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry. TenX Keane Acquisition vs. Cocrystal Pharma Pulmatrix BioLineRx Pieris Pharmaceuticals MIRA Pharmaceuticals BioXcel Therapeutics Cyclo Therapeutics GlycoMimetics Spruce Biosciences Enlivex Therapeutics Cocrystal Pharma (NASDAQ:COCP) and TenX Keane Acquisition (NASDAQ:TENK) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations. Does the media refer more to COCP or TENK? In the previous week, Cocrystal Pharma had 3 more articles in the media than TenX Keane Acquisition. MarketBeat recorded 3 mentions for Cocrystal Pharma and 0 mentions for TenX Keane Acquisition. Cocrystal Pharma's average media sentiment score of 0.95 beat TenX Keane Acquisition's score of 0.00 indicating that Cocrystal Pharma is being referred to more favorably in the media. Company Overall Sentiment Cocrystal Pharma Positive TenX Keane Acquisition Neutral Does the MarketBeat Community favor COCP or TENK? Cocrystal Pharma received 23 more outperform votes than TenX Keane Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformCocrystal PharmaOutperform Votes2376.67% Underperform Votes723.33% TenX Keane AcquisitionN/AN/A Do insiders and institutionals hold more shares of COCP or TENK? 6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 70.5% of TenX Keane Acquisition shares are owned by institutional investors. 25.6% of Cocrystal Pharma shares are owned by insiders. Comparatively, 22.9% of TenX Keane Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable earnings and valuation, COCP or TENK? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCocrystal PharmaN/AN/A-$17.98M-$1.85-1.19TenX Keane AcquisitionN/AN/AN/AN/AN/A Is COCP or TENK more profitable? TenX Keane Acquisition's return on equity of 0.00% beat Cocrystal Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Cocrystal PharmaN/A -94.62% -78.24% TenX Keane Acquisition N/A N/A N/A Do analysts rate COCP or TENK? Cocrystal Pharma presently has a consensus price target of $7.00, indicating a potential upside of 218.18%. Given Cocrystal Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe Cocrystal Pharma is more favorable than TenX Keane Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00TenX Keane Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCocrystal Pharma beats TenX Keane Acquisition on 7 of the 10 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get TenX Keane Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TENK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENK vs. The Competition Export to ExcelMetricTenX Keane AcquisitionHolding Offices IndustryUnclassified SectorNASDAQ ExchangeMarket Cap$5.67M$259.01M$106.48M$8.85BDividend YieldN/A7.56%5.21%4.08%P/E RatioN/A2.181.0717.87Price / SalesN/A129.820.7386.14Price / CashN/A80.95100.2136.92Price / BookN/A73.09519.866.54Net IncomeN/A$32.40M$2.46M$226.15M TenX Keane Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENKTenX Keane AcquisitionN/A$0.85-12.3%N/A-91.1%$5.67MN/A0.00N/ACOCPCocrystal Pharma3.0786 of 5 stars$2.20+2.3%$7.00+218.2%+46.7%$22.37MN/A-1.1910PULMPulmatrix0.2893 of 5 stars$6.12+0.2%N/A+230.8%$22.34M$7.30M-2.3220BLRXBioLineRx1.9956 of 5 stars$0.28-15.2%$21.00+7,451.2%-81.7%$22.23M$4.80M-0.6240News CoverageHigh Trading VolumePIRSPieris Pharmaceuticals1.6352 of 5 stars$16.77+5.3%N/A+2.8%$22.14M$42.81M-1.39140Analyst UpgradeMIRAMIRA Pharmaceuticals1.6635 of 5 stars$1.32+4.8%$14.00+960.6%-58.0%$21.86MN/A-2.362News CoverageBTAIBioXcel Therapeutics4.5663 of 5 stars$0.51-10.5%$5.00+882.3%-86.7%$21.76M$1.38M-0.2490News CoverageGap DownHigh Trading VolumeCYTHCyclo Therapeutics2.9808 of 5 stars$0.73+4.3%$0.95+30.1%-40.2%$21.00M$1.08M-0.819News CoverageGLYCGlycoMimetics3.4718 of 5 stars$0.32flat$10.00+3,056.6%-79.2%$20.43M$10,000.000.0050Analyst ForecastGap UpSPRBSpruce Biosciences2.6551 of 5 stars$0.48-2.0%$4.00+727.6%-64.5%$19.96M$7.10M-0.5120Gap DownENLVEnlivex Therapeutics3.2366 of 5 stars$0.93+10.7%$6.00+545.6%-49.2%$19.90MN/A-0.7970Positive News Related Companies and Tools Related Companies COCP Alternatives PULM Alternatives BLRX Alternatives PIRS Alternatives MIRA Alternatives BTAI Alternatives CYTH Alternatives GLYC Alternatives SPRB Alternatives ENLV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TENK) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TenX Keane Acquisition Please log in to your account or sign up in order to add this asset to your watchlist. Share TenX Keane Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
